<DOC>
	<DOCNO>NCT01803412</DOCNO>
	<brief_summary>This phase III , multicenter , open-label , uncontrolled extension study male subject DMD open eligible US Canadian subject previously participate follow study drisapersen : DMD114876 , DMD114044 DMD114349 . Subjects receive 6mg/kg subcutaneous drisapersen weekly basis . For subject previously experience significant safety tolerability issue experience study , potential alternate intermittent dose arm give regimen 6 mg/kg weekly 8 week follow 4 week treatment . For subject experience previously experience significant safety/tolerability issue , side effect reaction intermittent dosing , intravenous dose make available .</brief_summary>
	<brief_title>A Study Safety , Tolerability &amp; Efficacy Long-term Administration Drisapersen US &amp; Canadian Subjects</brief_title>
	<detailed_description>In Part A study ( DMD115501 , original protocol ) , 21 subject enter study 3 US site complete 14 week treatment , 22 week follow-up . This protocol amendment , Part B study include 13 US Canadian center , 51 subject . In total study enroll approximately 72 subject . All subject commence Part B screen follow study schedule . The primary dosing arm drisapersen 6 mg/kg SC injection ( ) week . For subject previously experience significant safety tolerability issue experience study , potential alternate intermittent dose arm give regimen 6 mg/kg/wk 8 week follow 4 week treatment . For subject experience previously experience significant safety/tolerability issue , intravenous dose make available . This study minimum duration participation . Subjects vary time study participation depend enter one eligible study , permit continue study time withdraw base protocol-defined criterion , BioMarin stop study .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Participation eligible drisapersen study follow : ( A ) Prior DMD114876 subject : Subjects complete 24 week doubleblind treatment 24 week posttreatment phase study DMD114876 OR Subjects withdraw treatment portion study DMD114876 due meeting laboratory safety stop criterion may eligible enrol extension study : laboratory parameter lead stop resolve ; principal investigator ( PI ) consider benefit treatment drisapersen outweigh risk individual subject ; follow consultation Medical Monitor ( B ) Prior DMD114044 Subjects : US subject complete study DMD114044 another country want return US participate study DMD115501 , upon agreement DMD115501 Investigator OR US citizen participate DMD114044 withdraw study due meeting laboratory safety stop criterion may eligible enrol DMD115501 : laboratory parameter lead stop resolve ; PI consider benefit treatment drisapersen outweigh risk individual subject ; follow consultation Medical Monitor upon agreement DMD115501 investigator ( C ) Prior DMD114349 Subjects : US subject participate complete study DMD114044 another country enter ongoing openlabel extension study DMD114349 country outside US wish withdraw DMD114349 return US participate study DMD115501 , upon agreement DMD115501 investigator . Canadian subject participate DMD114349 study OR Canadian subject withdrew treatment portion study DMD114349 due meeting laboratory safety stop criterion may eligible enroll extension study laboratory parameter lead stop resolve ; PI consider benefit treatment drisapersen outweigh risk individual subject ; follow consultation Medical Monitor . Continued use glucocorticoid minimum 60 day prior study entry reasonable expectation subject remain steroids duration study . Changes cessation glucocorticoid discretion PI consultation subject/parent Medical Monitor . If subject steroid , involvement study need discuss medical monitor . Willing able comply protocol requirement procedure ( exception assessment require subject ambulant , subject lose ambulation ) Able give inform assent and/or consent writing sign subject and/or parent ( ) /legal guardian ( accord local regulation ) Subject serious adverse experience meet safety stop criterion remain unresolved study DMD114876 , DMD114044 , DMD114349 , opinion investigator could attributable study medication , ongoing . Once resolve , subject may eligible enrol follow PI consultation Medical Monitor Use anticoagulant , antithrombotics antiplatelet agent , previous treatment investigational drug except drisapersen , within 28 day first administration study medication Participation investigational clinical trial within 30 day prior start screen , clinical study . If subject participate study within 6 month , discuss medical monitor prior study entry . History significant medical disorder may confound interpretation either efficacy safety data ( e.g . current history renal liver disease/impairment , history inflammatory illness ) Symptomatic cardiomyopathy . If subject leave ventricular ejection fraction &lt; 45 % Screening , investigator discus inclusion subject study medical monitor A platelet count lower limit normal screening . A retest within screen period permissible within normal range subject may enter study .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>GSK2402968</keyword>
	<keyword>open-label extension</keyword>
	<keyword>safety</keyword>
	<keyword>drisapersen</keyword>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>tolerability</keyword>
	<keyword>Quality Life</keyword>
</DOC>